# The Role of Vasopressin in the Social Deficits of Autism

> **NCT01962870** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 68 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Vasopressin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01962870
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-05-30
- **Final completion:** 2017-05-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962870, "The Role of Vasopressin in the Social Deficits of Autism". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01962870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*